{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:59:33Z","timestamp":1790272773452,"version":"4.1.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02217-3","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:50:11Z","timestamp":1790265011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence"],"prefix":"10.1007","author":[{"given":"Neha","family":"Rathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Kanaujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gond Kanchankumari","family":"Subhashchandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamu","family":"Bhotiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Rajinikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"4","key":"2217_CR1","first-page":"e70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76(4):e70090.","journal-title":"CA Cancer J Clin"},{"key":"2217_CR2","doi-asserted-by":"crossref","unstructured":"Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. 2025. Volume 13\u20132025.","DOI":"10.3389\/fpubh.2025.1622954"},{"issue":"3","key":"2217_CR3","first-page":"287","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent. 2025;5(3):287\u201396.","journal-title":"J Natl Cancer Cent"},{"key":"2217_CR4","doi-asserted-by":"publisher","unstructured":"Subhashchandra GK, Kanaujiya S, Kumar A, Verma M, Arya DK, Pandey P, Mittal K, Rajinikanth PS. Multifunctional electrospun nanofibers for cancer therapy and regenerative reconstruction: current progress and future prospects. International Journal of Pharmaceutics. 2026;7:126962. https:\/\/doi.org\/10.1016\/j.ijpharm.2026.126962","DOI":"10.1016\/j.ijpharm.2026.126962"},{"issue":"3","key":"2217_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2217_CR6","unstructured":"Society AC. Cancer Facts & Figs. 2024. 2024 [cited 2026; Annual cancer statistics report including incidence, mortality, and survival trends]."},{"key":"2217_CR7","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2026). 2026 April 2, 2026]; Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"issue":"3","key":"2217_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s13193-021-01342-4","volume":"12","author":"A Goel","year":"2021","unstructured":"Goel A, et al. Surgical Management of Locoregional Recurrence in Breast Cancer. Indian J Surg Oncol. 2021;12(3):616\u201323.","journal-title":"Indian J Surg Oncol"},{"key":"2217_CR9","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3389\/fonc.2024.1308343","volume":"14","author":"FY Lv","year":"2024","unstructured":"Lv FY, et al. Locoregional recurrence and survival of breast-conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer. Front Oncol. 2024;14:2234\u2013X943.","journal-title":"Front Oncol"},{"issue":"7","key":"2217_CR10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","volume":"77","author":"S Tohme","year":"2017","unstructured":"Tohme S, Simmons RL, Tsung A. Surgery for Cancer: A Trigger for Metastases. Cancer Res. 2017;77(7):1548\u201352.","journal-title":"Cancer Res"},{"issue":"Pt 3","key":"2217_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.semcancer.2022.01.006","volume":"86","author":"X Cheng","year":"2022","unstructured":"Cheng X, et al. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 2022;86(Pt 3):408\u201319.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2217_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ctm2.24","volume":"10","author":"F Tang","year":"2020","unstructured":"Tang F, et al. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199\u2013223.","journal-title":"Clin Transl Med"},{"issue":"8","key":"2217_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd.2016.39","volume":"15","author":"JN Fullerton","year":"2016","unstructured":"Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016;15(8):551\u201367.","journal-title":"Nat Rev Drug Discov"},{"key":"2217_CR14","doi-asserted-by":"crossref","unstructured":"Krall JA-O et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. LID\u2009\u2013\u200910.1126\/scitranslmed.aan3464 [doi] LID - eaan3464. science translational medicine, 2018(1946\u20136242 (Electronic)).","DOI":"10.1126\/scitranslmed.aan3464"},{"issue":"25","key":"2217_CR15","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808\u201315.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2217_CR16","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdq683","volume":"22","author":"HA Azim Jr","year":"2011","unstructured":"Azim HA Jr., et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22(9):1939\u201347.","journal-title":"Ann Oncol"},{"issue":"18","key":"2217_CR17","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","volume":"23","author":"C Praga","year":"2005","unstructured":"Praga C, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(18):4179\u201391.","journal-title":"J Clin Oncol"},{"key":"2217_CR18","doi-asserted-by":"publisher","unstructured":"Jeselsohn, R., et al., ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol, 2015. 12(10):573-83. https:\/\/doi.org\/10.1038\/nrclinonc.2015.117","DOI":"10.1038\/nrclinonc.2015.117"},{"issue":"0 3","key":"2217_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","volume":"418 Pt 3","author":"R Clarke","year":"2015","unstructured":"Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer\u2013An overview and update. Mol Cell Endocrinol. 2015;418 Pt 3(0 3):220\u201334.","journal-title":"Mol Cell Endocrinol"},{"key":"2217_CR20","unstructured":"Cardoso F et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020. Ann Oncol., 2018(1569\u20138041 (Electronic))."},{"issue":"9","key":"2217_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"2217_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556\u201367.","journal-title":"N Engl J Med"},{"issue":"21","key":"2217_CR23","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024;391(21):1981\u201391.","journal-title":"N Engl J Med"},{"key":"2217_CR24","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.esmorw.2024.100061","volume":"5","author":"L Rached","year":"2024","unstructured":"Rached L, et al. Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer. ESMO Real World Data Digit Oncol. 2024;5:100061.","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"1","key":"2217_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","volume":"14","author":"Q Chen","year":"2019","unstructured":"Chen Q, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019;14(1):89\u201397.","journal-title":"Nat Nanotechnol"},{"issue":"24","key":"2217_CR26","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1039\/D4TB00659C","volume":"12","author":"M Xiang","year":"2024","unstructured":"Xiang M, et al. Dissolving microneedles for transdermal drug delivery in cancer immunotherapy. J Mater Chem B. 2024;12(24):5812\u201322.","journal-title":"J Mater Chem B"},{"issue":"Electronic","key":"2217_CR27","first-page":"1872","volume":"127","author":"Y Ye","year":"2018","unstructured":"Ye Y, et al. Polymeric microneedles for transdermal protein delivery. Adv Drug Deliv Rev. 2018;127(Electronic):1872\u20138294.","journal-title":"Adv Drug Deliv Rev"},{"issue":"Electronic","key":"2217_CR28","first-page":"1947","volume":"8","author":"MR Prausnitz","year":"2017","unstructured":"Prausnitz MR. Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. Annu Rev Chem Biomol Eng. 2017;8(Electronic):1947\u20135446.","journal-title":"Annu Rev Chem Biomol Eng"},{"issue":"10","key":"2217_CR29","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1021\/acsbiomaterials.9b00961","volume":"5","author":"H Kim","year":"2019","unstructured":"Kim H, et al. Biodegradable Microneedle Patch Delivering Antigenic Peptide\u2013Hyaluronate Conjugate for Cancer Immunotherapy. ACS Biomaterials Sci Eng. 2019;5(10):5150\u20138.","journal-title":"ACS Biomaterials Sci Eng"},{"issue":"Print","key":"2217_CR30","first-page":"1663","volume":"16","author":"K Chen","year":"2025","unstructured":"Chen K, et al. Advances in clinical applications of microneedle. Front Pharmacol. 2025;16(Print):1663\u20139812.","journal-title":"Front Pharmacol"},{"issue":"15","key":"2217_CR31","doi-asserted-by":"publisher","first-page":"22362","DOI":"10.1021\/acsami.5c01155","volume":"17","author":"Z Luo","year":"2025","unstructured":"Luo Z, et al. Implantable Immunostimulant Microneedle Patch for Post-Surgical Prevention of Cancer Recurrence and Distant Tumor Inhibition. ACS Appl Mater Interfaces. 2025;17(15):22362\u201374.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10095","key":"2217_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","volume":"390","author":"NG Rouphael","year":"2017","unstructured":"Rouphael NG, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017;390(10095):649\u201358.","journal-title":"Lancet"},{"issue":"10439","key":"2217_CR33","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","volume":"403","author":"I Adigweme","year":"2024","unstructured":"Adigweme I, et al. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1\/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial. Lancet. 2024;403(10439):1879\u201392.","journal-title":"Lancet"},{"key":"2217_CR34","doi-asserted-by":"publisher","first-page":"106841","DOI":"10.1016\/j.jddst.2025.106841","volume":"107","author":"Y Yang","year":"2025","unstructured":"Yang Y, et al. Dissolving cinnamaldehyde HA\/PVA microneedles for the treatment of skin diseases caused by Microsporum canis. J Drug Deliv Sci Technol. 2025;107:106841.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"2217_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11095-023-03621-x","volume":"41","author":"D Ando","year":"2024","unstructured":"Ando D, et al. Fabrication and Characterization of Dissolving Microneedles for Transdermal Drug Delivery of Apomorphine Hydrochloride in Parkinson\u2019s Disease. Pharm Res. 2024;41(1):153\u201363.","journal-title":"Pharm Res"},{"issue":"Electronic","key":"2217_CR36","first-page":"1878","volume":"176","author":"S Huang","year":"2024","unstructured":"Huang S, et al. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848\/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer. Acta Biomater. 2024;176(Electronic):1878\u20137568.","journal-title":"Acta Biomater"},{"issue":"Electronic","key":"2217_CR37","first-page":"1873","volume":"379","author":"Y Yin","year":"2025","unstructured":"Yin Y, et al. Microneedle patch-involved local therapy synergized with immune checkpoint inhibitor for pre- and post-operative cancer treatment. J Control Release. 2025;379(Electronic):1873\u20134995.","journal-title":"J Control Release"},{"issue":"16","key":"2217_CR38","doi-asserted-by":"publisher","first-page":"e2416270","DOI":"10.1002\/advs.202416270","volume":"12","author":"Z Chu","year":"2025","unstructured":"Chu Z, et al. Implanted Microneedles Loaded with Sparfloxacin and Zinc-Manganese Sulfide Nanoparticles Activates Immunity for Postoperative Triple-Negative Breast Cancer to Prevent Recurrence and Metastasis. Adv Sci (Weinh). 2025;12(16):e2416270.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"2217_CR39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/sla.0b013e318208fc2a","volume":"253","author":"M Yi","year":"2011","unstructured":"Yi M, et al. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011;253(3):572\u20139. https:\/\/doi.org\/10.1097\/sla.0b013e318208fc2a","journal-title":"Ann Surg"},{"key":"2217_CR40","doi-asserted-by":"crossref","unstructured":"Arya DK, et al. Co-delivery of gefitinib and lycorine hydrochloride enriched liposome functionalized with trastuzumab and iRGD for synergistic therapy of metastatic breast cancer. African Journal of Biomedical Research; 2024.","DOI":"10.53555\/AJBR.v27i4S.5174"},{"issue":"20","key":"2217_CR41","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/JCO.19.02806","volume":"38","author":"TA Buchholz","year":"2020","unstructured":"Buchholz TA, Ali S, Hunt KK. Multidisciplinary Management of Locoregional Recurrent Breast Cancer. J Clin Oncol. 2020;38(20):2321\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2217_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.radonc.2006.04.006","volume":"79","author":"HM Nielsen","year":"2006","unstructured":"Nielsen HM, et al. Loco-regional recurrence after mastectomy in high-risk breast cancer\u2013risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol. 2006;79(2):147\u201355.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2217_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jnci\/djh297","volume":"97","author":"J Ragaz","year":"2005","unstructured":"Ragaz J, et al. Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial. JNCI: J Natl Cancer Inst. 2005;97(2):116\u201326.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"2217_CR44","volume-title":"Subtypes of Breast Cancer. BTI - Breast Cancer, in Breast Cancer","author":"E Orrantia-Borunda","year":"2022","unstructured":"Orrantia-Borunda E, et al. Subtypes of Breast Cancer. BTI - Breast Cancer, in Breast Cancer. Exon Publications: Brisbane (AU): M. HN, Editor.; 2022."},{"issue":"7","key":"2217_CR45","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00432-018-2644-2","volume":"144","author":"A Ignatov","year":"2018","unstructured":"Ignatov A, et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018;144(7):1347\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2217_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.breast.2011.07.008","volume":"21","author":"S Park","year":"2012","unstructured":"Park S, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21(1):50\u20137. https:\/\/doi.org\/10.1016\/j.breast.2011.07.008","journal-title":"Breast"},{"issue":"6","key":"2217_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, et al. Differences in breast cancer survival by molecular subtypes in the United States. Biomarkers Prev. 2018;27(6):619\u201326.","journal-title":"Biomarkers Prev"},{"issue":"20","key":"2217_CR48","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke H, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2217_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2217_CR50","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s12032-012-0388-4","volume":"30","author":"K Pogoda","year":"2013","unstructured":"Pogoda K, et al. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388.","journal-title":"Med Oncol"},{"issue":"9","key":"2217_CR51","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34(9):927\u201335.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2217_CR52","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2217_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2217_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9(2):176\u201398.","journal-title":"Cancer Discov"},{"issue":"7","key":"2217_CR55","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"},{"issue":"1","key":"2217_CR56","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):10232.","journal-title":"Nat Commun"},{"key":"2217_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2340\/1651-226X.2024.33008","volume":"63","author":"M Otterlei Fj\u00f8rtoft","year":"2024","unstructured":"Otterlei Fj\u00f8rtoft M, Huse K, Rye IH. The Tumor Immune Microenvironment in Breast Cancer Progression. Acta Oncol. 2024;63:359\u201367.","journal-title":"Acta Oncol"},{"issue":"23","key":"2217_CR58","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-13-0790","volume":"19","author":"NU Lin","year":"2013","unstructured":"Lin NU, et al. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19(23):6404\u201318.","journal-title":"Clin Cancer Res"},{"key":"2217_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Sig Transduct Target Ther. 2021;6:362.","journal-title":"Sig Transduct Target Ther"},{"issue":"6","key":"2217_CR60","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-16-0284","volume":"5","author":"JB Foote","year":"2017","unstructured":"Foote JB, et al. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunol Res. 2017;5(6):468\u201379.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2217_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2217_CR62","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356\u201364.","journal-title":"J Clin Invest"},{"issue":"1","key":"2217_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109\u201318.","journal-title":"Cell Res"},{"key":"2217_CR64","doi-asserted-by":"publisher","first-page":"102158","DOI":"10.1016\/j.mtbio.2025.102158","volume":"34","author":"H Yu","year":"2025","unstructured":"Yu H, et al. Light-controlled pyroptosis via redox-responsive microneedles enhances photodynamic\u2013epigenetic immunotherapy in breast cancer. Mater Today Bio. 2025;34:102158.","journal-title":"Mater Today Bio"},{"key":"2217_CR65","doi-asserted-by":"crossref","unstructured":"He J et al. Design and Evaluation of Dissolving Microneedles for Enhanced Dermal Delivery of Propranolol Hydrochloride. Pharmaceutics, 2021. 13(4).","DOI":"10.3390\/pharmaceutics13040579"},{"issue":"7391","key":"2217_CR66","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/483531a","volume":"483","author":"CG Begley","year":"2012","unstructured":"Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature. 2012;483(7391):531\u20133.","journal-title":"Nature"},{"issue":"52","key":"2217_CR67","doi-asserted-by":"publisher","first-page":"2305834","DOI":"10.1002\/adma.202305834","volume":"35","author":"Z Sartawi","year":"2023","unstructured":"Sartawi Z, et al. Glass Microneedles: A Case Study for Regulatory Approval Using a Quality by Design Approach. Adv Mater. 2023;35(52):2305834.","journal-title":"Adv Mater"},{"issue":"4","key":"2217_CR68","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s44222-023-00141-6","volume":"2","author":"M Zheng","year":"2024","unstructured":"Zheng M, et al. Microneedle biomedical devices. Nat Reviews Bioeng. 2024;2(4):324\u201342.","journal-title":"Nat Reviews Bioeng"},{"key":"2217_CR69","doi-asserted-by":"publisher","first-page":"1480571","DOI":"10.3389\/fcell.2024.1480571","volume":"12","author":"C Liu","year":"2024","unstructured":"Liu C, et al. Radiation-induced skin reactions: oxidative damage mechanism and antioxidant protection. Front Cell Dev Biol. 2024;12:1480571.","journal-title":"Front Cell Dev Biol"},{"key":"2217_CR70","doi-asserted-by":"crossref","unstructured":"Kumar S, Pezo RC. Role of Circulating Tumor DNA in Adapting Immunotherapy Approaches in Breast Cancer. Curr Oncol, 2025.32(7).","DOI":"10.3390\/curroncol32070373"},{"key":"2217_CR71","doi-asserted-by":"publisher","first-page":"114980","DOI":"10.1016\/j.jconrel.2026.114980","volume":"395","author":"J Zhou","year":"2026","unstructured":"Zhou J, et al. Microneedle array platforms for drug delivery and biomarker sensing: From skin mechanics guided design to scalable manufacture for clinical utility. J Control Release. 2026;395:114980.","journal-title":"J Control Release"},{"key":"2217_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2022.05.045","volume":"348","author":"Z Sartawi","year":"2022","unstructured":"Sartawi Z, Blackshields C, Faisal W. Dissolving microneedles: Applications and growing therapeutic potential. J Controlled Release. 2022;348:186\u2013205.","journal-title":"J Controlled Release"},{"key":"2217_CR73","first-page":"100623","volume":"12","author":"MN Rahma","year":"2026","unstructured":"Rahma MN, et al. Dissolving microneedles for inflammatory diseases: Advances in formulation strategies and therapeutic applications. Int J Pharmaceutics: X. 2026;12:100623.","journal-title":"Int J Pharmaceutics: X"},{"issue":"37","key":"2217_CR74","doi-asserted-by":"publisher","first-page":"42135","DOI":"10.1021\/acsomega.5c04565","volume":"10","author":"V Colaco","year":"2025","unstructured":"Colaco V, et al. Microneedles as Gateways: Smart Nanoparticle Delivery for Enhanced Breast Cancer Treatment. ACS Omega. 2025;10(37):42135\u201350.","journal-title":"ACS Omega"},{"issue":"1","key":"2217_CR75","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nbt.3104","volume":"33","author":"SB Stephan","year":"2015","unstructured":"Stephan SB, et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33(1):97\u2013101.","journal-title":"Nat Biotechnol"},{"issue":"28","key":"2217_CR76","doi-asserted-by":"publisher","first-page":"e1801527","DOI":"10.1002\/adma.201801527","volume":"30","author":"S Yu","year":"2018","unstructured":"Yu S, et al. Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade. Adv Mater. 2018;30(28):e1801527.","journal-title":"Adv Mater"},{"issue":"1","key":"2217_CR77","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1038\/ncomms8556","volume":"6","author":"SA Bencherif","year":"2015","unstructured":"Bencherif SA, et al. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun. 2015;6(1):7556.","journal-title":"Nat Commun"},{"issue":"1","key":"2217_CR78","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nbt.3071","volume":"33","author":"J Kim","year":"2015","unstructured":"Kim J, et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2015;33(1):64\u201372.","journal-title":"Nat Biotechnol"},{"key":"2217_CR79","doi-asserted-by":"publisher","first-page":"122918","DOI":"10.1016\/j.ijpharm.2023.122918","volume":"638","author":"G Pandey","year":"2023","unstructured":"Pandey G, et al. Multilayered nanofibrous scaffold of Polyvinyl alcohol\/gelatin\/poly (lactic-co-glycolic acid) enriched with hemostatic\/antibacterial agents for rapid acute hemostatic wound healing. Int J Pharm. 2023;638:122918.","journal-title":"Int J Pharm"},{"key":"2217_CR80","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.2147\/IJN.S464046","volume":"19","author":"S Kanaujiya","year":"2024","unstructured":"Kanaujiya S, et al. Resveratrol-Ampicillin Dual-Drug Loaded Polyvinylpyrrolidone\/Polyvinyl Alcohol Biomimic Electrospun Nanofiber Enriched with Collagen for Efficient Burn Wound Repair. Int J Nanomed. 2024;19:5397\u2013418.","journal-title":"Int J Nanomed"},{"key":"2217_CR81","doi-asserted-by":"publisher","first-page":"151109","DOI":"10.1016\/j.ijbiomac.2026.151109","volume":"353","author":"N Abraham","year":"2026","unstructured":"Abraham N, et al. Multifunctional bilayered nanofibrous scaffold of chitosan\/poly(caprolactone) enriched with simvastatin and thymoquinone for accelerated diabetic wound healing. Int J Biol Macromol. 2026;353:151109.","journal-title":"Int J Biol Macromol"},{"key":"2217_CR82","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.1038\/srep07914","volume":"5","author":"SF Lahiji","year":"2015","unstructured":"Lahiji SF, Dangol M, Jung H. A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery. Sci Rep. 2015;5:7914.","journal-title":"Sci Rep"},{"issue":"4","key":"2217_CR83","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1021\/acsabm.4c01532","volume":"8","author":"S Yadav","year":"2025","unstructured":"Yadav S, et al. Poly (vinyl alcohol)\/Polycaprolactone nanofiber enriched with lichenysin against multidrug-resistance bacterial infection in wound healing: In vitro studies and in vivo evaluation in Wistar rats. ACS Appl Bio Mater. 2025;8(4):2847\u201366.","journal-title":"ACS Appl Bio Mater"},{"issue":"2","key":"2217_CR84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/03639045.2025.2453533","volume":"51","author":"S Shah","year":"2025","unstructured":"Shah S, et al. Docetaxel and niclosamide-loaded nanofiber systems for improved chemo-therapeutic activity and resistance reversal in prostate cancer. Drug Dev Ind Pharm. 2025;51(2):132\u201343.","journal-title":"Drug Dev Ind Pharm"},{"key":"2217_CR85","volume-title":"Regulatory Considerations for Microneedling Products: Guidance for Industry and Food and Drug Administration Staff","author":"Administration USFaD","year":"2020","unstructured":"Administration USFaD. Regulatory Considerations for Microneedling Products: Guidance for Industry and Food and Drug Administration Staff. Silver Spring (MD); 2020."},{"issue":"14","key":"2217_CR86","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","volume":"64","author":"YC Kim","year":"2012","unstructured":"Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547\u201368.","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"2217_CR87","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.3390\/polym15204059","volume":"15","author":"X Yu","year":"2023","unstructured":"Yu X, Zhao J, Fan D. The Progress in the Application of Dissolving Microneedles in Biomedicine. polymers. 2023;15(20):4059.","journal-title":"polymers"},{"key":"2217_CR88","doi-asserted-by":"publisher","first-page":"1054029","DOI":"10.3389\/fonc.2022.1054029","volume":"12","author":"H Mahmudi","year":"2022","unstructured":"Mahmudi H, et al. Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease. Front Oncol. 2022;12:1054029.","journal-title":"Front Oncol"},{"issue":"1","key":"2217_CR89","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59\u201373.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2217_CR90","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","volume":"36","author":"IL Wapnir","year":"2018","unstructured":"Wapnir IL, et al. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. 2018;36(11):1073\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2217_CR91","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/17512433.2019.1637252","volume":"12","author":"AJ Genuino","year":"2019","unstructured":"Genuino AJ, et al. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2019;12(8):815\u201324.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"18","key":"2217_CR92","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMc2203316","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, R.J.N.E.J.o M, Dent. Pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(18):1771\u20132.","journal-title":"N Engl J Med"},{"key":"2217_CR93","doi-asserted-by":"publisher","first-page":"1831221","DOI":"10.3389\/fimmu.2026.1831221","volume":"17","author":"Y Chen","year":"2026","unstructured":"Chen Y, et al. Recent advances in dissolving microneedles for breast cancer immunotherapy: local delivery and tumor microenvironment remodeling. Front Immunol. 2026;17:1831221.","journal-title":"Front Immunol"},{"key":"2217_CR94","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijpharm.2018.12.022","volume":"556","author":"S Bhatnagar","year":"2019","unstructured":"Bhatnagar S, et al. Dissolvable microneedle patch containing doxorubicin and docetaxel is effective in 4T1 xenografted breast cancer mouse model. Int J Pharm. 2019;556:263\u201375.","journal-title":"Int J Pharm"},{"key":"2217_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mser.2016.03.001","volume":"104","author":"E Larra\u00f1eta","year":"2016","unstructured":"Larra\u00f1eta E, et al. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Mater Sci Engineering: R: Rep. 2016;104:1\u201332.","journal-title":"Mater Sci Engineering: R: Rep"},{"issue":"8","key":"2217_CR96","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1021\/js980042+","volume":"87","author":"S Henry","year":"1998","unstructured":"Henry S, et al. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998;87(8):922\u20135.","journal-title":"J Pharm Sci"},{"issue":"17","key":"2217_CR97","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1021\/acs.nanolett.3c01914","volume":"23","author":"T Wang","year":"2023","unstructured":"Wang T, et al. Steerable Microneedles Enabling Deep Delivery of Photosensitizers and CRISPR\/Cas9 Systems for Effective Combination Cancer Therapy. Nano Lett. 2023;23(17):7990\u20139.","journal-title":"Nano Lett"},{"issue":"1","key":"2217_CR98","first-page":"93","volume":"13","author":"P Makvandi","year":"2021","unstructured":"Makvandi P, et al. Engineering Microneedle Patches for Improved Penetration: Analysis, Skin Models and Factors Affecting Needle Insertion. Nanomicro Lett. 2021;13(1):93.","journal-title":"Nanomicro Lett"},{"issue":"1","key":"2217_CR99","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40486-024-00204-2","volume":"12","author":"R Dave","year":"2024","unstructured":"Dave R, et al. Engineering microscopic delivery systems: a review of dissolving microneedle design, fabrication, and function. Micro Nano Syst Lett. 2024;12(1):14.","journal-title":"Micro Nano Syst Lett"},{"key":"2217_CR100","doi-asserted-by":"publisher","first-page":"115055","DOI":"10.1016\/j.addr.2023.115055","volume":"201","author":"LK Vora","year":"2023","unstructured":"Vora LK, et al. Long-acting microneedle formulations. Adv Drug Deliv Rev. 2023;201:115055.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2217_CR101","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2006.10.017","volume":"117","author":"HS Gill","year":"2007","unstructured":"Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Controlled Release. 2007;117(2):227\u201337.","journal-title":"J Controlled Release"},{"issue":"1","key":"2217_CR102","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11095-005-8498-8","volume":"23","author":"W Martanto","year":"2006","unstructured":"Martanto W, et al. Microinfusion using hollow microneedles. Pharm Res. 2006;23(1):104\u201313.","journal-title":"Pharm Res"},{"issue":"Electronic","key":"2217_CR103","first-page":"1873","volume":"285","author":"EM Migdadi","year":"2018","unstructured":"Migdadi EM, et al. Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride. J Control Release. 2018;285(Electronic):1873\u20134995.","journal-title":"J Control Release"},{"issue":"6","key":"2217_CR104","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/ph17060791","volume":"17","author":"H Omidian","year":"2024","unstructured":"Omidian H, Dey Chowdhury S. Swellable Microneedles in Drug Delivery and Diagnostics. Pharmaceuticals. 2024;17(6):791.","journal-title":"Pharmaceuticals"},{"issue":"23","key":"2217_CR105","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1002\/adfm.201200864","volume":"22","author":"RF Donnelly","year":"2012","unstructured":"Donnelly RF, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22(23):4879\u201390.","journal-title":"Adv Funct Mater"},{"issue":"5","key":"2217_CR106","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/adma.200701205","volume":"20","author":"SP Sullivan","year":"2008","unstructured":"Sullivan SP, Murthy N, Prausnitz MR. Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer Microneedles. Adv Mater. 2008;20(5):933\u20138.","journal-title":"Adv Mater"},{"key":"2217_CR107","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2022.05.045","volume":"348","author":"Z Sartawi","year":"2022","unstructured":"Sartawi Z, Blackshields C, Faisal W. Dissolving microneedles: Applications and growing therapeutic potential. J Control Release. 2022;348:186\u2013205.","journal-title":"J Control Release"},{"issue":"8","key":"2217_CR108","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nm.2182","volume":"16","author":"SP Sullivan","year":"2010","unstructured":"Sullivan SP, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915\u201320.","journal-title":"Nat Med"},{"issue":"12","key":"2217_CR109","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1021\/acs.molpharmaceut.4c00894","volume":"21","author":"BHJ Gowda","year":"2024","unstructured":"Gowda BHJ, et al. Microneedles as an Emerging Platform for Transdermal Delivery of Phytochemicals. Mol Pharm. 2024;21(12):6007\u201333.","journal-title":"Mol Pharm"},{"issue":"4","key":"2217_CR110","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/10717541003667798","volume":"17","author":"RF Donnelly","year":"2010","unstructured":"Donnelly RF, Raj TR, Singh, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187\u2013207.","journal-title":"Drug Deliv"},{"issue":"31","key":"2217_CR111","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.1039\/D6TB01042C","volume":"14","author":"S Kanaujiya","year":"2026","unstructured":"Kanaujiya S, et al. Cyclodextrin-based biomaterials for tissue regeneration: design strategies, biomedical applications, and translational insights. J Mater Chem B. 2026;14(31):9583\u2013627.","journal-title":"J Mater Chem B"},{"issue":"3","key":"2217_CR112","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jconrel.2012.05.030","volume":"161","author":"S Liu","year":"2012","unstructured":"Liu S, et al. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Control Release. 2012;161(3):933\u201341.","journal-title":"J Control Release"},{"key":"2217_CR113","doi-asserted-by":"publisher","unstructured":"Chudzi\u0144ska J, Wawrzy\u0144czak A, Feliczak-Guzik A. Microneedles Based on a Biodegradable Polymer\u2014Hyaluronic Acid. Polymers. 2024;16. https:\/\/doi.org\/10.3390\/polym16101396.","DOI":"10.3390\/polym16101396"},{"issue":"20","key":"2217_CR114","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1016\/j.biomaterials.2012.03.056","volume":"33","author":"CJ Ke","year":"2012","unstructured":"Ke CJ, et al. Multidrug release based on microneedle arrays filled with pH-responsive PLGA hollow microspheres. Biomaterials. 2012;33(20):5156\u201365.","journal-title":"Biomaterials"},{"issue":"4","key":"2217_CR115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40204-020-00143-2","volume":"9","author":"V Onesto","year":"2020","unstructured":"Onesto V, et al. Engineered PLGA-PVP\/VA based formulations to produce electro-drawn fast biodegradable microneedles for labile biomolecule delivery. Prog Biomater. 2020;9(4):203\u201317.","journal-title":"Prog Biomater"},{"key":"2217_CR116","doi-asserted-by":"crossref","unstructured":"Chen, M.C., et al., Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination. Biomaterials, 2013. 34(12): p. 3077-86.","DOI":"10.1016\/j.biomaterials.2012.12.041"},{"issue":"2","key":"2217_CR117","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/adfm.201102012","volume":"22","author":"K Tsioris","year":"2012","unstructured":"Tsioris K, et al. Fabrication of Silk Microneedles for Controlled-Release Drug Delivery. Adv Funct Mater. 2012;22(2):330\u20135.","journal-title":"Adv Funct Mater"},{"key":"2217_CR118","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ijbiomac.2020.12.177","volume":"170","author":"N Dabholkar","year":"2021","unstructured":"Dabholkar N, et al. Biodegradable microneedles fabricated with carbohydrates and proteins: Revolutionary approach for transdermal drug delivery. Int J Biol Macromol. 2021;170:602\u201321.","journal-title":"Int J Biol Macromol"},{"issue":"30","key":"2217_CR119","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.1016\/j.biomaterials.2012.06.065","volume":"33","author":"K Lee","year":"2012","unstructured":"Lee K, Jung H. Drawing lithography for microneedles: a review of fundamentals and biomedical applications. Biomaterials. 2012;33(30):7309\u201326.","journal-title":"Biomaterials"},{"issue":"3","key":"2217_CR120","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jconrel.2013.05.026","volume":"170","author":"JD Kim","year":"2013","unstructured":"Kim JD, et al. Droplet-born air blowing: novel dissolving microneedle fabrication. J Control Release. 2013;170(3):430\u20136.","journal-title":"J Control Release"},{"issue":"2","key":"2217_CR121","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijpharm.2018.03.031","volume":"544","author":"CPP Pere","year":"2018","unstructured":"Pere CPP, et al. 3D printed microneedles for insulin skin delivery. Int J Pharm. 2018;544(2):425\u201332.","journal-title":"Int J Pharm"},{"issue":"Electronic","key":"2217_CR122","first-page":"1873","volume":"604","author":"L Zhang","year":"2021","unstructured":"Zhang L, et al. Fabrication, evaluation and applications of dissolving microneedles. Int J Pharm. 2021;604(Electronic):1873\u20133476.","journal-title":"Int J Pharm"},{"issue":"2","key":"2217_CR123","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0333102417737765","volume":"38","author":"EL Spierings","year":"2018","unstructured":"Spierings EL, et al. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia. 2018;38(2):215\u201324.","journal-title":"Cephalalgia"},{"key":"2217_CR124","doi-asserted-by":"crossref","unstructured":"Davis, S.P., et al., Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech, 2004. 37(8): p. 1155-63.","DOI":"10.1016\/j.jbiomech.2003.12.010"},{"key":"2217_CR125","doi-asserted-by":"crossref","unstructured":"Park JH, M.R. Allen Mg Fau - Prausnitz, and, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release., 2005(0168\u20133659 (Print)).","DOI":"10.1016\/j.jconrel.2005.02.002"},{"issue":"4","key":"2217_CR126","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13346-015-0237-z","volume":"5","author":"RE Lutton","year":"2015","unstructured":"Lutton RE, et al. Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation. Drug Deliv Transl Res. 2015;5(4):313\u201331.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"2217_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"9","key":"2217_CR128","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1021\/acsnano.6b04989","volume":"10","author":"Y Ye","year":"2016","unstructured":"Ye Y, et al. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. ACS Nano. 2016;10(9):8956\u201363.","journal-title":"ACS Nano"},{"issue":"4","key":"2217_CR129","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nmat3550","volume":"12","author":"PC DeMuth","year":"2013","unstructured":"DeMuth PC, et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013;12(4):367\u201376.","journal-title":"Nat Mater"},{"issue":"10","key":"2217_CR130","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142\u20139.","journal-title":"Nat Immunol"},{"issue":"5","key":"2217_CR131","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830\u201342.","journal-title":"Immunity"},{"issue":"7","key":"2217_CR132","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11(7):1018\u201330.","journal-title":"Cell Rep"},{"issue":"11","key":"2217_CR133","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2217_CR134","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","volume":"3","author":"TA Waldmann","year":"2015","unstructured":"Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3(3):219\u201327.","journal-title":"Cancer Immunol Res"},{"issue":"0732\u20130582 Print","key":"2217_CR135","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22(0732\u20130582 Print):745\u201363.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2217_CR136","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech SM, Cui W. Transcriptional control of effector and memory CD8\u2009+\u2009T cell differentiation. Nat Rev Immunol. 2012;12(11):749\u201361.","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"2217_CR137","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","volume":"131","author":"R Romee","year":"2018","unstructured":"Romee R, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018;131(23):2515\u201327.","journal-title":"Blood"},{"issue":"12","key":"2217_CR138","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677\u201386.","journal-title":"Trends Immunol"},{"issue":"1","key":"2217_CR139","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49\u201361.","journal-title":"Immunity"},{"issue":"10","key":"2217_CR140","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396.","journal-title":"Nat Immunol"},{"issue":"6230","key":"2217_CR141","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"issue":"6382","key":"2217_CR142","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"4","key":"2217_CR143","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1021\/acs.nanolett.5b05030","volume":"16","author":"C Wang","year":"2016","unstructured":"Wang C, et al. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Nano Lett. 2016;16(4):2334\u201340.","journal-title":"Nano Lett"},{"issue":"8","key":"2217_CR144","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"2217_CR145","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum IB, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74(3):665\u201374.","journal-title":"Cancer Res"},{"issue":"1","key":"2217_CR146","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14\u201320.","journal-title":"Immunity"},{"issue":"4","key":"2217_CR147","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"key":"2217_CR148","doi-asserted-by":"publisher","first-page":"16075","DOI":"10.1038\/natrevmats.2016.75","volume":"1","author":"Y Lu","year":"2016","unstructured":"Lu Y, et al. Bioresponsive materials. Nat Reviews Mater. 2016;1:16075.","journal-title":"Nat Reviews Mater"},{"issue":"3","key":"2217_CR149","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12668-025-01935-1","volume":"15","author":"P Famta","year":"2025","unstructured":"Famta P, et al. Establishment and Evaluation of Paclitaxel and Simvastatin-Laden Nanofibers for Post-surgical Tumor Recurrence in Breast Cancer. BioNanoScience. 2025;15(3):366.","journal-title":"BioNanoScience"},{"issue":"2","key":"2217_CR150","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri.2015.3","volume":"16","author":"SN Mueller","year":"2016","unstructured":"Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol. 2016;16(2):79\u201389.","journal-title":"Nat Rev Immunol"},{"key":"2217_CR151","doi-asserted-by":"crossref","unstructured":"Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity., 2014(1097\u20134180 (Electronic)).","DOI":"10.1016\/j.immuni.2014.12.007"},{"issue":"8","key":"2217_CR152","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.it.2019.06.002","volume":"40","author":"SL Park","year":"2019","unstructured":"Park SL, Gebhardt T, Mackay LK. Tissue-Resident Memory T Cells in Cancer Immunosurveillance. Trends Immunol. 2019;40(8):735\u201347.","journal-title":"Trends Immunol"},{"key":"2217_CR153","doi-asserted-by":"crossref","unstructured":"Hettinga JA-O, Carlisle R. Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. LID\u2009\u2013\u200910.3390\/vaccines8030534 [doi] LID\u2009\u2013\u2009534. Vaccines (Basel), 2020(2076-393X (Print)).","DOI":"10.3390\/vaccines8030534"},{"issue":"11","key":"2217_CR154","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138.","journal-title":"Nat Immunol"},{"issue":"2","key":"2217_CR155","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"2217_CR156","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:1545\u20133278.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2217_CR157","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361.","journal-title":"Nat Med"},{"issue":"9","key":"2217_CR158","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"2217_CR159","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1021\/acsnano.5b05043","volume":"10","author":"M-C Chen","year":"2016","unstructured":"Chen M-C, Lin Z-W, Ling M-H. Near-Infrared Light-Activatable Microneedle System for Treating Superficial Tumors by Combination of Chemotherapy and Photothermal Therapy. ACS Nano. 2016;10(1):93\u2013101.","journal-title":"ACS Nano"},{"issue":"6","key":"2217_CR160","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28(6):690\u2013714.","journal-title":"Cancer Cell"},{"key":"2217_CR161","doi-asserted-by":"publisher","first-page":"101706","DOI":"10.1016\/j.mtbio.2025.101706","volume":"32","author":"Y Sun","year":"2025","unstructured":"Sun Y, et al. Dual inhibition of DNA damage repair sensitizes photodynamic therapy for triple negative breast cancer. Mater Today Bio. 2025;32:101706.","journal-title":"Mater Today Bio"},{"issue":"3","key":"2217_CR162","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1021\/acsbiomaterials.6b00515","volume":"3","author":"JA Stinson","year":"2017","unstructured":"Stinson JA, et al. Silk Fibroin Microneedles for Transdermal Vaccine Delivery. ACS Biomaterials Sci Eng. 2017;3(3):360\u20139.","journal-title":"ACS Biomaterials Sci Eng"},{"key":"2217_CR163","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejpb.2019.05.001","volume":"140","author":"AH Sabri","year":"2019","unstructured":"Sabri AH, et al. Expanding the applications of microneedles in dermatology. Eur J Pharm Biopharm. 2019;140:121\u201340.","journal-title":"Eur J Pharm Biopharm"},{"key":"2217_CR164","doi-asserted-by":"publisher","first-page":"152873","DOI":"10.1016\/j.ijbiomac.2026.152873","volume":"370","author":"Riyamol","year":"2026","unstructured":"Riyamol, et al. A review of extraction methods, downstream processing, and green recovery innovations of microbial extracellular polysaccharides. Int J Biol Macromol. 2026;370:152873.","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"2217_CR165","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41551-020-00650-4","volume":"5","author":"KTM Tran","year":"2021","unstructured":"Tran KTM, et al. Transdermal microneedles for the programmable burst release of multiple vaccine payloads. Nat Biomedical Eng. 2021;5(9):998\u20131007.","journal-title":"Nat Biomedical Eng"},{"issue":"2","key":"2217_CR166","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13555-016-0120-y","volume":"6","author":"FN Bray","year":"2016","unstructured":"Bray FN, et al. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb). 2016;6(2):185\u2013206.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"19","key":"2217_CR167","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2217_CR168","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2011.12.026","volume":"159","author":"A Vrdoljak","year":"2012","unstructured":"Vrdoljak A, et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release. 2012;159(1):34\u201342.","journal-title":"J Control Release"},{"key":"2217_CR169","unstructured":"Agency EM. Scientific recommendations on classification of advanced therapy medicinal products. 2025; Available from: https:\/\/www.ema.europa.eu\/"},{"issue":"1","key":"2217_CR170","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1038\/s41467-025-61549-9","volume":"16","author":"J Yang","year":"2025","unstructured":"Yang J, et al. Microneedle-based integrated pharmacokinetic and pharmacodynamic evaluation platform for personalized medicine. Nat Commun. 2025;16(1):6260.","journal-title":"Nat Commun"},{"issue":"245","key":"2217_CR171","doi-asserted-by":"publisher","first-page":"245ra93","DOI":"10.1126\/scitranslmed.3008973","volume":"6","author":"V Favaudon","year":"2014","unstructured":"Favaudon V, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014;6(245):245ra93.","journal-title":"Sci Transl Med"},{"issue":"11","key":"2217_CR172","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261\u20138.","journal-title":"Nat Biotechnol"},{"issue":"7662","key":"2217_CR173","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"key":"2217_CR174","doi-asserted-by":"crossref","unstructured":"Ott, P.A., et al., An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017. 547(7662): p. 217-221.","DOI":"10.1038\/nature22991"},{"issue":"3","key":"2217_CR175","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1021\/nn304235j","volume":"7","author":"M Zaric","year":"2013","unstructured":"Zaric M, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano. 2013;7(3):2042\u201355.","journal-title":"ACS Nano"},{"issue":"7823","key":"2217_CR176","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107\u201312.","journal-title":"Nature"},{"key":"2217_CR177","doi-asserted-by":"crossref","unstructured":"ldawood FK, Andar A, Desai S. A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications. Polymers. 2021; 13(16):2815.","DOI":"10.3390\/polym13162815"},{"issue":"6","key":"2217_CR178","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/0115748855262877231114050949","volume":"19","author":"N Rajan","year":"2024","unstructured":"Rajan N, Kanaujiya S. Unlocking the Potential of Drug Delivery Systems: A Comprehensive Review of Formulation Strategies and Technologies in the Field of Pharmaceutics. Curr Drug Therapy. 2024;19(6):661\u201377.","journal-title":"Curr Drug Therapy"},{"issue":"11","key":"2217_CR179","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","volume":"26","author":"HA Parsons","year":"2020","unstructured":"Parsons HA, et al. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020;26(11):2556\u201364.","journal-title":"Clin Cancer Res"},{"issue":"Electronic","key":"2217_CR180","first-page":"1178","volume":"13","author":"Z Naseri","year":"2018","unstructured":"Naseri Z, et al. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomed. 2018;13(Electronic):1178\u20132013.","journal-title":"Int J Nanomed"},{"issue":"10","key":"2217_CR181","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/03639045.2025.2529437","volume":"51","author":"SN Patil","year":"2025","unstructured":"Patil SN, et al. Microneedle-based wearable sensors: a new frontier in real-time biomarker monitoring. Drug Dev Ind Pharm. 2025;51(10):1149\u201366.","journal-title":"Drug Dev Ind Pharm"},{"issue":"8","key":"2217_CR182","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri855","volume":"2","author":"C Th\u00e9ry","year":"2002","unstructured":"Th\u00e9ry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569\u201379.","journal-title":"Nat Rev Immunol"},{"key":"2217_CR183","doi-asserted-by":"crossref","unstructured":"Ye Y et al. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. ACS Nano., 2016(1936-086X (Electronic)).","DOI":"10.1021\/acsnano.6b04989"},{"issue":"302","key":"2217_CR184","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas I, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2217_CR185","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1078-0432.CCR-17-3375","volume":"25","author":"MC Vozenin","year":"2019","unstructured":"Vozenin MC, et al. The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients. Clin Cancer Res. 2019;25(1):35\u201342.","journal-title":"Clin Cancer Res"},{"key":"2217_CR186","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.acr.2019.03.006","volume":"143","author":"A Basu","year":"2019","unstructured":"Basu A, et al. Immunotherapy in breast cancer: Current status and future directions. Adv Cancer Res. 2019;143:295\u2013349.","journal-title":"Adv Cancer Res"},{"issue":"11","key":"2217_CR187","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdn386","volume":"19","author":"R Demicheli","year":"2008","unstructured":"Demicheli R, et al. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19(11):1821\u20138.","journal-title":"Ann Oncol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02217-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02217-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02217-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:02:35Z","timestamp":1790269355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02217-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":187,"alternative-id":["2217"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02217-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics and Consent to Participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}